After a recent series B round, Beacon Therapeutics has boosted its finances by $170m, bringing its total funding to date to $290m, as it looks to advance in the crowded field of gene therapies for t
The study also indicated that Phylogica Ltd. ’s proprietary CPP fusion process significantly improved the efficacy of existing anticancer drugs including the EGFR inhibiting antibody cetuximab ( M
One company’s growth-leader is another’s undesirable diversification – that’s the takeaway from the July 30 transaction in which Pfizer Inc. purchased Baxter International Inc. ’s vaccines busi